• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Cigna Ventures | Health Care Venture Capital

Cigna Ventures | Health Care Venture Capital

  • Strategy
  • Partners
  • Team
  • News
  • Contact

MedAvail and MYOS RENS Technology Announce Closing of Business Combination

November 18, 2020

MedAvail, Inc. (“MedAvail”), a leading technology-enabled pharmacy organization that embeds pharmacy services directly into clinics and other points of care through its proprietary technology, announced the completion of its previously announced business combination with MYOS RENS Technology, Inc. (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle. The combined company will focus on the MedAvail business and its shares will trade on the Nasdaq Capital Market under the new trading symbol “MDVL.” The current MYOS RENS muscle health business will be spun off as a private unaffiliated company.

Read the full article

Filed Under: News, Partnership Activity

Primary Sidebar

Categories

  • News
  • Partnership Activity

More news

  • Three-Way Merger Combines Focus on Physician and Patient Engagement with Industry-Leading Technology Platform to Create the Nation’s Premier, Value Based Kidney Care Provider March 22, 2022
  • New $450M Investment in Cigna Ventures to Drive Health Care Transformation, Innovation, and Growth March 7, 2022
  • Cigna Ventures invests in Flume Health March 4, 2022
  • Babyscripts Raises $7.5M in Additional Series B Funding to Roll Out Virtual Maternity Care Solution to Providers Across the U.S., Enabling Greater Access to Care November 30, 2021
  • Zerigo Health Raises $43M in Series B Funding October 21, 2021
  • Headspace, Ginger finalize merger to form $3B mental health company October 14, 2021
  • Executive Spotlight – Featuring Tom Richards, Cigna SVP and Global Lead for Strategy and Business Development September 22, 2021

Footer

  • Strategy
  • Partners
  • Team
  • News
  • Contact

By contacting Cigna Ventures through this website, you agree and acknowledge that information you submit will not be considered or treated as confidential or proprietary unless and until a separate agreement is signed, and that Cigna Ventures and its affiliates are under no obligation to review your submission or to enter into any agreement, investment or transaction associated with the submission. In no event will Cigna Ventures or any of its affiliates be limited in, or restricted from, the pursuit of any opportunities, either alone or with third parties.

The information contained herein does not constitute a distribution, an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction in which such distribution or offer is not authorized. In particular, the information herein is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities in the United States (U.S.) or for the benefit of any U.S. person (being residents of the United States. or partnerships or corporations organized under the laws of the United States), nor in any other country.

The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc.

Privacy Policy | Terms of Use | Accessibility

© 2022 Cigna. All rights reserved

This site is protected by reCAPTCHA and the Google. Privacy Policy and Terms of Service apply.